Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.

Autor: Hayes TK; Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Neel NF; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Hu C; Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Gautam P; Institute for Molecular Medicine Finland, University of Helsinki, 00290 Helsinki, Finland., Chenard M; Merck Research Laboratories, Boston, MA 02115, USA., Long B; Merck Research Laboratories, Boston, MA 02115, USA., Aziz M; Departments of Cancer and Cell Biology, Translational Genomics Research Institute, Phoenix, AZ 85004, USA., Kassner M; Departments of Cancer and Cell Biology, Translational Genomics Research Institute, Phoenix, AZ 85004, USA., Bryant KL; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Pierobon M; Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110, USA., Marayati R; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Kher S; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., George SD; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Xu M; Divisions of Oncology, Department of Internal Medicine, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA; Division of Medical Oncology, Alvin J. Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA., Wang-Gillam A; Divisions of Oncology, Department of Internal Medicine, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA; Division of Medical Oncology, Alvin J. Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA., Samatar AA; Merck Research Laboratories, Boston, MA 02115, USA., Maitra A; Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Wennerberg K; Institute for Molecular Medicine Finland, University of Helsinki, 00290 Helsinki, Finland., Petricoin EF 3rd; Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110, USA., Yin HH; Departments of Cancer and Cell Biology, Translational Genomics Research Institute, Phoenix, AZ 85004, USA., Nelkin B; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA., Cox AD; Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Yeh JJ; Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Der CJ; Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address: cjder@med.unc.edu.

Publikováno v: Cancer cell [Cancer Cell] 2016 Jan 11; Vol. 29 (1), pp. 75-89. Date of Electronic Publication: 2015 Dec 24.

A comparative evaluation of ultrasound molecular imaging, perfusion imaging, and volume measurements in evaluating response to therapy in patient-derived xenografts.

Autor: Streeter JE; Joint Department of Biomedical _Engineering, University of North _Carolina, North Carolina State _University, Chapel Hill, NC, USA. padayton@bme.unc.edu., Herrera-Loeza SG, Neel NF, Yeh JJ, Dayton PA

Publikováno v: Technology in cancer research & treatment [Technol Cancer Res Treat] 2013 Aug; Vol. 12 (4), pp. 311-21. Date of Electronic Publication: 2013 Jan 25.

The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery.

Autor: Neel NF; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Martin TD, Stratford JK, Zand TP, Reiner DJ, Der CJ

Publikováno v: Genes & cancer [Genes Cancer] 2011 Mar; Vol. 2 (3), pp. 275-87.

IQGAP1 is a novel CXCR2-interacting protein and essential component of the "chemosynapse".

Autor: Neel NF; Department of Veterans Affairs, Nashville, Tennessee, United States of America., Sai J, Ham AJ, Sobolik-Delmaire T, Mernaugh RL, Richmond A

Publikováno v: PloS one [PLoS One] 2011; Vol. 6 (8), pp. e23813. Date of Electronic Publication: 2011 Aug 18.